BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roumenina LT, Chadebech P, Bodivit G, Vieira-Martins P, Grunenwald A, Boudhabhay I, Poillerat V, Pakdaman S, Kiger L, Jouard A, Audureau E, Pirenne F, Galactéros F, Frémeaux-Bacchi V, Bartolucci P. Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol 2020;95:456-64. [PMID: 31990387 DOI: 10.1002/ajh.25742] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Piccin A, O'Connor-Byrne N, Daves M, Lynch K, Farshbaf AD, Martin-Loeches I. Autoimmune disease and sickle cell anaemia: 'Intersecting pathways and differential diagnosis'. Br J Haematol 2022. [PMID: 35244209 DOI: 10.1111/bjh.18109] [Reference Citation Analysis]
2 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 de Azevedo JTC, Malmegrim KCR. Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives. Immunol Lett 2020;224:1-11. [PMID: 32437728 DOI: 10.1016/j.imlet.2020.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Meuleman MS, Fremeaux-Bacchi V, Roumenina LT, Chauvet S. Ex Vivo Complement Activation on Endothelial Cells: Research and Translational Value. Trends Mol Med 2021;27:418-21. [PMID: 33648869 DOI: 10.1016/j.molmed.2021.01.008] [Reference Citation Analysis]
5 Shet AS, Lizarralde-Iragorri MA, Naik RP. The molecular basis for the prothrombotic state in sickle cell disease. Haematologica 2020;105:2368-79. [PMID: 33054077 DOI: 10.3324/haematol.2019.239350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hebbel RP, Vercellotti GM. Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease. Am J Hematol 2021;96:1505-17. [PMID: 34331722 DOI: 10.1002/ajh.26308] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Grunenwald A, Roumenina LT. The Benefits of Complement Measurements for the Clinical Practice. Methods Mol Biol 2021;2227:1-20. [PMID: 33847926 DOI: 10.1007/978-1-0716-1016-9_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bozza MT, Jeney V. Pro-inflammatory Actions of Heme and Other Hemoglobin-Derived DAMPs. Front Immunol 2020;11:1323. [PMID: 32695110 DOI: 10.3389/fimmu.2020.01323] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
9 Tampaki A, Gavriilaki E, Varelas C, Anagnostopoulos A, Vlachaki E. Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing. Blood Rev 2021;48:100805. [PMID: 33504459 DOI: 10.1016/j.blre.2021.100805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Boudhabhay I, Grunenwald A, Roumenina LT. Complement C3 Deposition on Endothelial Cells Revealed by Flow Cytometry. In: Roumenina LT, editor. The Complement System. New York: Springer US; 2021. pp. 97-105. [DOI: 10.1007/978-1-0716-1016-9_9] [Reference Citation Analysis]
11 Aradottir SS, Kristoffersson AC, Roumenina LT, Bjerre A, Kashioulis P, Palsson R, Karpman D. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. Front Immunol 2021;12:690821. [PMID: 34177949 DOI: 10.3389/fimmu.2021.690821] [Reference Citation Analysis]
12 [DOI: 10.1101/2020.04.16.044321] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Motta I, Giannotta J, Ferraresi M, Barbullushi K, Revelli N, Graziadei G, Barcellini W, Fattizzo B. Autoimmune Hemolytic Anemia as a Complication of Congenital Anemias. A Case Series and Review of the Literature. J Clin Med 2021;10:3439. [PMID: 34362222 DOI: 10.3390/jcm10153439] [Reference Citation Analysis]
14 Ashouri R, Fangman M, Burris A, Ezenwa MO, Wilkie DJ, Doré S. Critical Role of Hemopexin Mediated Cytoprotection in the Pathophysiology of Sickle Cell Disease. Int J Mol Sci 2021;22:6408. [PMID: 34203861 DOI: 10.3390/ijms22126408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Varelas C, Gavriilaki E, Sakellari I, Klonizakis P, Koravou E, Christodoulou I, Mavrikou I, Kourelis A, Chatzopoulou F, Chatzidimitriou D, Touloumenidou T, Papalexandri A, Anagnostopoulos A, Vlachaki E. Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center. JCM 2022;11:937. [DOI: 10.3390/jcm11040937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Detzel MS, Schmalohr BF, Steinbock F, Hopp MT, Ramoji A, Paul George AA, Neugebauer U, Imhof D. Revisiting the interaction of heme with hemopexin. Biol Chem 2021;402:675-91. [PMID: 33581700 DOI: 10.1515/hsz-2020-0347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle Cell Disease: Role of Oxidative Stress and Antioxidant Therapy. Antioxidants (Basel) 2021;10:296. [PMID: 33669171 DOI: 10.3390/antiox10020296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Poillerat V, Gentinetta T, Leon J, Wassmer A, Edler M, Torset C, Luo D, Tuffin G, Roumenina LT. Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation. Front Immunol 2020;11:1684. [PMID: 32849588 DOI: 10.3389/fimmu.2020.01684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Belcher JD, Nguyen J, Chen C, Abdulla F, Conglin R, Ivy ZK, Cummings J, Dudler T, Vercellotti GM. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease. Transl Res 2022:S1931-5244(22)00152-9. [PMID: 35878790 DOI: 10.1016/j.trsl.2022.06.018] [Reference Citation Analysis]
20 Varelas C, Tampaki A, Sakellari I, Anagnostopoulos Α, Gavriilaki E, Vlachaki E. Complement in Sickle Cell Disease: Are We Ready for Prime Time? J Blood Med 2021;12:177-87. [PMID: 33790681 DOI: 10.2147/JBM.S287301] [Reference Citation Analysis]